Differentiated Thyroid Carcinoma

  • Luca GiovanellaEmail author
  • Giorgio Treglia


Differentiated thyroid cancer (DTC), arising from thyroid follicular epithelial cells, is the most common endocrine malignancy. DTC is characterized by low morbidity and mortality because its clinical course is generally indolent.

This chapter provides a brief summary on the management of DTC. Some diagnostic images of DTC are also provided.


Differentiated thyroid carcinoma Papillary Follicular Thyroid cancer 


  1. 1.
    American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper CS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214CrossRefGoogle Scholar
  2. 2.
    Verburg FA, Mader U, Tanase K et al (2013) Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumour invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 98:172–180CrossRefPubMedGoogle Scholar
  3. 3.
    Reiners C, Hanscheid H, Luster M et al (2011) Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol 7:589–595CrossRefPubMedGoogle Scholar
  4. 4.
    Diessl S, Holzberger B, Mäder U et al (2012) Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin Endocrinol 76:586–592CrossRefGoogle Scholar
  5. 5.
    Giovanella L (2008) Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 46:1067–1073PubMedGoogle Scholar
  6. 6.
    Giovanella L, Trimboli P, Verburg FA et al (2013) Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 40:874–880CrossRefPubMedGoogle Scholar
  7. 7.
    Giovanella L, Treglia G, Ceriani L et al (2014) Detectable thyroglobulin with negative anatomical imaging and radioiodine scan in differentiated thyroid cancer patients: what to do? Nuklearmedizin 53:1–10CrossRefPubMedGoogle Scholar
  8. 8.
    Schlumberger M, Mancusi F, Baudin E et al (1997) 131I therapy for elevated thyroglobulin levels. Thyroid 7:273–276CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Nuclear Medicine, Thyroid and PET/CT CenterOncology Institute of Southern SwitzerlandBellinzona and LuganoSwitzerland

Personalised recommendations